Evommune, Inc. (EVMN)

Evommune, Inc. is a clinical-stage biotechnology company developing medicines for chronic inflammatory diseases. The company focuses on blocking key drivers of inflammation in conditions affecting the skin and the gut, where many patients do not respond adequately to existing treatments.

Its lead programs include EVO756, an oral small molecule that targets the MRGPRX2 receptor on mast cells and is being studied in chronic spontaneous urticaria and atopic dermatitis, and EVO301, a long-acting biologic being developed for atopic dermatitis and ulcerative colitis.

Evommune was incorporated in 2020 and is headquartered in Palo Alto, California. Its common stock trades on the New York Stock Exchange under the ticker EVMN following its initial public offering in 2025.